Literature DB >> 16849747

Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study.

Paul De Leyn1, Sigrid Stroobants, Walter De Wever, Toni Lerut, Willy Coosemans, Georges Decker, Philippe Nafteux, Dirk Van Raemdonck, Luc Mortelmans, Kristiaan Nackaerts, Johan Vansteenkiste.   

Abstract

PURPOSE: Mediastinal restaging after induction therapy for non-small-cell lung cancer remains a difficult and controversial issue. The goal of this prospective study was to compare the performance of integrated positron emission tomography (PET)--computed tomography (CT) and remediastinoscopy in the evaluation of mediastinal lymph node metastasis after induction chemotherapy. PATIENTS AND METHODS: Thirty consecutive stage IIIA-N2 non-small-cell lung cancer patients surgically treated at our institution were entered onto this prospective study. N2 disease was proven by cervical mediastinoscopy, at which a mean number of 3.8 lymph node levels were biopsied. After completion of induction chemotherapy, the mediastinum was reassessed by integrated PET-CT and remediastinoscopy. All patients underwent thoracotomy with attempted complete resection and systematic nodal dissection.
RESULTS: PET-CT showed no evidence of nodal disease (N0) in 13 patients, Hilar nodal disease (N1) disease in three patients, and residual mediastinal disease (N2) in 14 patients. Remediastinoscopy was positive in only five patients. The preinduction involved lymph node level could be accurately re-evaluated in 18 patients. This was not the case in the other 12 because of extensive fibrosis and adhesions. In 17 patients, persistent N2 disease was found at thoracotomy. The sensitivity, specificity, and accuracy of PET-CT were 77%, 92%, and 83%, respectively. These parameters for remediastinoscopy were 29%, 100%, and 60%, respectively. Sensitivity (P < .0001) and accuracy (P = .012) were significantly better for PET-CT.
CONCLUSION: After a thorough staging mediastinoscopy, postinduction remediastinoscopy had a disappointing sensitivity because of adhesions and fibrosis. Integrated PET-CT yielded a better result than that obtained in previous studies with side-by-side PET and CT images.

Entities:  

Mesh:

Year:  2006        PMID: 16849747     DOI: 10.1200/JCO.2006.05.6341

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  21 in total

Review 1.  The role of endobronchial ultrasound versus mediastinoscopy for non-small cell lung cancer.

Authors:  Katarzyna Czarnecka-Kujawa; Kazuhiro Yasufuku
Journal:  J Thorac Dis       Date:  2017-03       Impact factor: 2.895

Review 2.  The role of induction therapy for resectable non-small cell lung cancer.

Authors:  Thomas E Stinchcombe; Mark A Socinski
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Hypofractionated radiotherapy with tomotherapy for patients with hepatic oligometastases: retrospective analysis of two institutions.

Authors:  Jong Hoon Lee; Joo Hwan Lee; Hong Seok Jang; Hyo Chun Lee; Jung Won Lee; Dae Gyu Kang; Byoung Yong Shim; Bong-Hyeon Kye; Hyung Jin Kim; Hyeon-Min Cho; Young Jin Suh; Sung Hwan Kim
Journal:  Clin Exp Metastasis       Date:  2013-02-06       Impact factor: 5.150

4.  Intraoperative frozen sections of the regional lymph nodes contribute to surgical decision-making in non-small cell lung cancer patients.

Authors:  Wei Li; Xue-Ning Yang; Ri-Qiang Liao; Qiang Nie; Song Dong; Hao-Ran Zhai; Yi-Long Wu; Wen-Zhao Zhong
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

5.  Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.

Authors:  R Taylor Ripley; Kei Suzuki; Kay See Tan; Prasad S Adusumilli; James Huang; Bernard J Park; Robert J Downey; Nabil P Rizk; Valerie W Rusch; Manjit Bains; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-19       Impact factor: 5.209

Review 6.  Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound.

Authors:  Neal Navani; Stephen G Spiro; Sam M Janes
Journal:  Nat Rev Clin Oncol       Date:  2009-05       Impact factor: 66.675

7.  Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803.

Authors:  Michael T Jaklitsch; Lin Gu; Todd Demmy; David H Harpole; Thomas A D'Amico; Robert J McKenna; Mark J Krasna; Leslie J Kohman; Scott J Swanson; Malcolm M DeCamp; Xiaofei Wang; Susan Barry; David J Sugarbaker
Journal:  J Thorac Cardiovasc Surg       Date:  2013-07       Impact factor: 5.209

Review 8.  The role of surgery in the treatment of stage III non-small-cell lung cancer.

Authors:  Amy E Gallo; Jessica S Donington
Journal:  Curr Oncol Rep       Date:  2007-07       Impact factor: 5.075

Review 9.  Management of locally advanced non small cell lung cancer from a surgical perspective.

Authors:  Millie S Roy; Jessica S Donington
Journal:  Curr Treat Options Oncol       Date:  2007-02

10.  The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.